McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.

Awang DV. Parthenocide: demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5:95-8.

Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9. View abstract.

Foster S. Feverfew, Tanacetum parthenium, botanical series #310. Austin, TX: Am Botanical Council, 1996.

Kuritzky A, Elhacham Y, Yerushalmi Z, et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201. (Abstract 293P)

McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology. US Headache Consortium, April 2000. Available at: www.aan.com/cgi-bin/whatsnewlink.pl?loc=/public/practiceguidelines.

Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2000;3:CD002286. View abstract.

Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9. View abstract.

Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-5. View abstract.

Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blind, placebo-controlled study. Ann Rheum Dis 1989;48:547-9. View abstract.

Awang DVC. Prescribing therapeutic feverfew (Tancetum pathrnium (L.) Schultz Bip., syn. Chrysanthemumparthenium (L.) Bernh). Int Med 1998;1:11-3.

Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 1987;39:459-65. View abstract.

Wong HC. Is feverfew a pharmacologic agent? CMAJ 1999;160:21-2. View abstract.

de Weerdt GJ, Bootsman HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30.

Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313-20. View abstract.

Williams CA, Hoult JR, Harborne JB, et al. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 1995;38:267-70. View abstract.

Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;1:1071-4. View abstract.

Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 1982;8:653-60. View abstract.

Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990;42:553-7. View abstract.

Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:447-9. View abstract.

Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry 1999;51:417-23. View abstract.

Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999;68:251-9. View abstract.

Barsby R, Salan U, Knight DW, Hoult JR. Irreversible inhibition of vascular reactivity by feverfew. Lancet 1991;338:1015. View abstract.

Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992;44:737-40. View abstract.

Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;2:776. View abstract.

Makheja AN, Bailey JM. The active principle in feverfew. Lancet 1981;2:1054. View abstract.

Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 1980;2:922-3. View abstract.

Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-9. View abstract.

Lamminpaa A, Estlander T, Jolanki R, Kanerva L. Occupational allergic contact dermatitis caused by decorative plants. Contact Dermatitis 1996;34:330-5. View abstract.

Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985;291:569-73. View abstract.

Murphy JJ, Heptinstall S, Mitchell JR. Randomized, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-92. View abstract.

Palevitch D, Earon G, Carasso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine- a double-blind, placebo-controlled study. Phytotherapy Res 1997;11:508-11.

Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8. View abstract.

Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;(1):CD002286. View abstract.

Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000;3:509-14. View abstract.

Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32. View abstract.

Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44:885-90. View abstract.

Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.

Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.

Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25:1031-41. View abstract.

Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53. View abstract.

Sur R, Martin K, Liebel F, et al. Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17:42-9. View abstract.

Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit. 2005;11:I65-69. View abstract.

Prusinski A, Durko A, and Niczyporuk-Turek A. [Feverfew as a prophylactic treatment of migraine]. Neurol.Neurochir.Pol. 1999;33 Suppl 5:89-95. View abstract.

Shrivastava R, Pechadre JC, and John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig. 2006;26:287-96. View abstract.

Sil'vestrov VP, Kinitin AV, and Chesnokova, IV. [Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis]. Ter.Arkh. 1991;63:7-11. View abstract.

Saraceno R, Chiricozzi A, Nistico SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J.Dermatolog.Treat. 2010;21:363-66. View abstract.

Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache 2011;51:1078-86. View abstract.

Sun-Edelstein, C. and Mauskop, A. Foods and supplements in the management of migraine headaches. Clin J Pain 2009;25(5):446-452. View abstract.

Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806. View abstract.

Christensen, L. P., Jakobsen, H. B., Paulsen, E., Hodal, L., and Andersen, K. E. Airborne Compositae dermatitis: monoterpenes and no parthenolide are released from flowering Tanacetum parthenium (feverfew) plants. Arch Dermatol Res 1999;291(7-8):425-431. View abstract.

Jovanovic, M. and Poljacki, M. [Compositae dermatitis]. Med Pregl. 2003;56(1-2):43-49. View abstract.

Gromek, D., Kisiel, W., Stojakowska, A., and Kohlmunzer, S. Attempts of chemical standardizing of Chrysanthemum parthenium as a prospective antimigraine drug. Pol.J.Pharmacol.Pharm. 1991;43(3):213-217. View abstract.

Silberstein, S. D. Preventive treatment of headaches. Curr Opin Neurol. 2005;18(3):289-292. View abstract.

Modi, S. and Lowder, D. M. Medications for migraine prophylaxis. Am Fam.Physician 1-1-2006;73(1):72-78. View abstract.

Kemper, K. J. and Breuner, C. C. Complementary, holistic, and integrative medicine: headaches. Pediatr.Rev. 2010;31(2):e17-e23. View abstract.

Czyz, M., Lesiak-Mieczkowska, K., Koprowska, K., Szulawska-Mroczek, A., and Wozniak, M. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br.J.Pharmacol. 2010;160(5):1144-1157. View abstract.

Loder, E., Burch, R., and Rizzoli, P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52(6):930-945. View abstract.

De Weerdt, C. J., Bootsma, H. P., and Hendriks, H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225-230. View abstract.

Hayes, N. A. and Foreman, J. C. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol 1987;39(6):466-470. View abstract.

Waller, P. C. and Ramsay, L. E. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 10-19-1985;291(6502):1128. View abstract.

Pfaffenrath V, Fischer M, Friede M, and et al. Clinical dose-response study for the investigation of efficacy and tolerability of Tanacetum parthenium in migraine prophylaxis. Deutscher Schmerzkongress; October 20-24, 1999, Munich, Germany. 1999;

Awang DV. Parthenocide: the demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5(4):95-98.

DeWeerdt CJ, Bootsman H, and Hendricks H. Herbal medicines in migraine prevention. Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomed 1996;3(3):225-230.

Palevitch D, Earon G, and Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11(7):508-511.

Kuritzky A, Elhacham Y, Yerushalmi Z, and et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201.

Ferro EC, Biagini AP, da Silva ÍE, Silva ML, Silva JR. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study. Acupunct Med. 2012 Dec;30(4):252-7. View abstract.

Heptinstall S. Feverfew--an ancient remedy for modern times? J R Soc Med. 1988 Jul;81(7):373-4. View abstract.

Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015 Apr 20;4:CD002286. [Epub ahead of print] View abstract.

Pareek A, Suthar M, Rathore G, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev. 2011;5(9):103-110. View abstract.

Guilbot A, Bangratz M, Ait Abdellah S, Lucas C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med. 2017;17(1):433. doi: 10.1186/s12906-017-1933-7. View abstract.

Zavarize P, Ngonga G, Pezzini A, Dalla Volta G. Combination of tanacethum partenium, 5-hjydrossitriptophan (5-Http) and magnesium in the prophylaxis of episodic migraine without aura (AURASTOP®) an observational study. Int J Neuro Brain Dis 2017;4(3):1-4. DOI: 10.15436/2377-1348.17.1630

Moscano F, Guiducci M, Maltoni L, et al. An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache. Ital J Pediatr. 2019;45(1):36. View abstract.

Alenzi KA, Alharbi FH, Tawhari FM, Fradees GS. Alteration of Coagulation Test Results and Vaginal Bleeding Associated With the Use of Feverfew (Tanacetum parthenium). J Med Cases 2021;12(1):9-12. View abstract.

Vikelis M, Dermitzakis EV, Vlachos GS, et al. Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. J Clin Med 2020;10(1):67. View abstract.